REG - CRISM Therapeutics - Innovation Passport Award

CRISM' TherapeuticsAnnouncement

02/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240902:nRSB4536Ca&default-theme=true

RNS Number : 4536C  CRISM Therapeutics Corporation  02 September 2024

2 September 2024

 

 

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

 

Innovation Passport Award

 

CRISM Therapeutics Corporation (AIM: CRTX), the innovative UK drug delivery
company focused on the localised delivery of chemotherapy drugs, is pleased to
announce that the Company has been awarded an Innovation Passport from the UK
Medicine and Healthcare products Regulatory Agency (MHRA) for its lead
programme, ChemoSeed® in high grade gliomas.

Award of an Innovation Passport is the first step in the MHRA's Innovative
Licensing and Access Pathway (ILAP) programme, which aims to accelerate the
development of innovative technologies in areas of unmet medical need by
providing access to a broad range of support throughout the product design,
development and approvals process.

CRISM Therapeutics' Innovation Passport award recognises ChemoSeed for high
grade gliomas as a promising innovative technology in an area of unmet medical
need and will enable CRISM to benefit from expedited and increased access to
medical, regulatory and scientific stakeholders. The next stage in the ILAP
programme for ChemoSeed is the creation of a Target Development Profile (TDP),
which will establish the optimal approach for the clinical development of
ChemoSeed.

The TDP is supported by the TDP toolkit, which seeks to bring clinically
important and promising medicines to patients faster and more efficiently.
Further details of the TDP toolkit are available at this link:
https://www.gov.uk/guidance/the-target-development-profile-toolkit
(https://www.gov.uk/guidance/the-target-development-profile-toolkit)

Separately, the Company is pleased to announce it has received £25,000 in
Grant Funding (the "Grant") from SPARK The Midlands, a network which aims to
bridge the gap between medical research discoveries of novel therapeutics,
medical devices and diagnostics and real-world clinical use. SPARK The
Midlands is the first UK branch of the globally recognised SPARK Stanford
programme found in over sixty locations globally. SPARK awarded the project
funding and support as part of its first cohort seeing the clear unmet
clinical need that CRISM is seeking to address. SPARK The Midlands is
supported by Innovate UK and the West Midlands Combined Authority.

Commenting on the Innovation Passport award and Grant, CRISM Therapeutics CEO
Andrew Webb said: "The award of this Innovation Passport for ChemoSeed in high
grade gliomas and access to the Innovative Licensing and Access Pathway
represents a significant milestone in the development of ChemoSeed and this
award alongside the grant funding from SPARK is an important endorsement for
CRISM Therapeutics.  The award validates the potential of our lead product to
change the treatment landscape for brain tumours and will assist CRISM in
potentially providing ChemoSeed to patients on a faster timescale compared
with traditional routes."

 

-Ends-

 

Enquiries:

 

 Company                         Nomad and Broker                  Financial PR
 CRISM Therapeutics Corporation  S.P. Angel Corporate Finance LLP  Burson Buchanan
 Andrew Webb, CEO                Richard Morrison                  Mark Court / Jamie Hooper

 Chris McConville, CSO           Adam Cowl                         CRISM@buchanancomms.co.uk
 via Burson Buchanan             +44 (0) 20 3470 0470              +44 (0) 20 7466 5000

 

 

 

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery
technology to improve the clinical performance of cancer treatments for solid
tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or
the resection margin following the removal of a tumour. This directs that
therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour
tissue or cover the entire resection margin. In the case of treating
high-grade glioma, ChemoSeeds can be implanted during surgery thereby
bypassing the blood brain barrier, which prevents other treatments from being
able to reach the tumour and be effective.

CRISM plans to submit a clinical trial application in H2 2024 for ChemoSeed®
in high-grade glioma.  Based on preclinical data, the Tessa Jowell BRAIN
MATRIX Scientific Advisory Board has approved ChemoSeed in a phase II platform
clinical trial which is an efficient and cost-effective clinical development
opportunity.

For more information please visit: https://www.crismtherapeutics.com/
(https://www.crismtherapeutics.com/)

About The Innovative Licensing and Access Pathway

The Innovative Licensing and Access Pathway (ILAP) aims to accelerate the time
to market, facilitating patient access to medicines. These medicines include
new chemical entities, biological medicines, new indications and repurposed
medicines.

The ILAP is open to both commercial and non-commercial developers of
medicines (UK based and or global). It comprises an Innovation Passport
designation, a target development profile (TDP) and provides applicants with
access to a toolkit to support the design, development and approvals process.

For more information:
https://www.gov.uk/guidance/innovative-licensing-and-access-pathway
(https://www.gov.uk/guidance/innovative-licensing-and-access-pathway)

About SPARK The Midlands

For more information on SPARK The Midlands, please visit:
https://www.sparkthemidlands.co.uk/ (https://www.sparkthemidlands.co.uk/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSSUESFELSEFU